The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)The Motley Fool • 03/11/25
S&P 500 ETF's Worst Week Since September: 5 Top Stocks Poised to RiseZacks Investment Research • 03/10/25
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 03/10/25
3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025Zacks Investment Research • 03/07/25
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 03/05/25
Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)Seeking Alpha • 03/04/25
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025Invezz • 03/04/25
Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'Investors Business Daily • 03/03/25
Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?Zacks Investment Research • 02/28/25
MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast CancerBusiness Wire • 02/25/25
European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV PreventionBusiness Wire • 02/24/25
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary CholangitisBusiness Wire • 02/20/25
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 02/20/25
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority ReviewBusiness Wire • 02/18/25
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 02/17/25